GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (NAS:BPTH) » Definitions » Earnings per Share (Diluted)

Bio-Path Holdings (Bio-Path Holdings) Earnings per Share (Diluted) : $-26.11 (TTM As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Bio-Path Holdings Earnings per Share (Diluted)?

Bio-Path Holdings's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-4.88. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-26.11.

Bio-Path Holdings's EPS (Basic) for the three months ended in Mar. 2024 was $-4.88. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-26.11.

Bio-Path Holdings's EPS without NRI for the three months ended in Mar. 2024 was $-5.71. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-26.53.

During the past 3 years, the average EPS without NRIGrowth Rate was 16.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 30.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 22.00% per year.

During the past 13 years, Bio-Path Holdings's highest 3-Year average EPS without NRI Growth Rate was 51.20% per year. The lowest was -208.50% per year. And the median was -3.50% per year.


Bio-Path Holdings Earnings per Share (Diluted) Historical Data

The historical data trend for Bio-Path Holdings's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Path Holdings Earnings per Share (Diluted) Chart

Bio-Path Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -64.80 -56.60 -31.00 -38.12 -33.63

Bio-Path Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.25 -10.60 -6.40 -4.23 -4.88

Competitive Comparison of Bio-Path Holdings's Earnings per Share (Diluted)

For the Biotechnology subindustry, Bio-Path Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Path Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's PE Ratio falls into.



Bio-Path Holdings Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Bio-Path Holdings's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-16.078-0)/0.478
=-33.64

Bio-Path Holdings's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-3.157-0)/0.647
=-4.88

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Bio-Path Holdings  (NAS:BPTH) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Bio-Path Holdings Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Bio-Path Holdings's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Path Holdings (Bio-Path Holdings) Business Description

Traded in Other Exchanges
Address
4710 Bellaire Boulevard, Suite 210, Bellaire, TX, USA, 77401
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.
Executives
Aline Sherwood director 347 BRANDYWINE DRIVE, IRWIN PA 15642
Tamaro Martina Molsbergen director 1307 SUMMERHILL DRIVE, MALVERN PA 19355
Mark P Colonnese director 4674 ANDREA POINTE, MARIETTA GA 30062
Peter Henry Nielsen director, officer: President, CEO & CFO 20651 PRINCE CREEK, KATY TX 77450
Paul Aubert director 4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE TX 77401
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Heath Cleaver director 4010 BALSAM FIR LN., SPRING TX 77386
Ulrich W. Mueller officer: COO & Secretary 17841 6TH AVE NW, SHORELINE WA 98177
Amy Sing director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Michael J. Garrison director 2626 SOUTH LOOP, SUITE 180, HOUSTON TX 77054
Douglas P Morris director 550 MADISON AVENUE, SUITE 3206, NEW YORK NY 10022
Gillian C Ivers-read director C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Thomas E Garrison director P O BOX 150248, OGDEN UT 84415